Moderna Sees COVID-19 Vaccine Surplus By 2022 If Constraints Ease
US Asked To Lift DPA Restrictions
Moderna, GSK and Bharat Biotech point to technology transfer, material shortages and manufacturing expertise as factors constraining COVID-19 vaccine supplies, rather than intellectual property rights. Meanwhile, Moderna's CEO forecasts a surplus of these vaccines by 2022.
You may also be interested in...
A possible alternative to Pfizer and Moderna’s COVID-19 vaccines, Providence Therapeutics’ mRNA candidate is seen moving into Phase III trials during the calendar first quarter of next year. While partners Everest Medicines and Biological E have kept the ball rolling, the Canadian biotech will seek further funding, CEO Brad Sorenson tells Scrip in this audio interview.
It’s counter-intuitive, but not signing a commercial contract with BioNTech and refusing US federal funding were two of several moves Pfizer made to speed up development of its COVID-19 vaccine, CEO Albert Bourla says. Now it’s looking to supply low- and middle-income countries.
Cipla is no novice in the vaccines segment and a potential link up for Moderna’s mRNA COVID-19 vaccine or with other firms could add an important lever in the 80-plus year-old Indian firm’s overall strategic thrust. Management has all along maintained a positive tone for coronavirus vaccine alliances.